Vimta Labs Ltd

Future Growth Expectations for Vimta Labs Limited based on the January 30, 2023 call: - The company targets to achieve INR 500 crores revenue by 2025-2026, retaining flexibility on the exact fiscal year. - Growth rate of 15-18% medium-term is targeted and management is optimistic about maintaining this. - New capacity additions expected by end of 2023 will address current capacity constraints enabling future growth. - Q4 FY24 anticipated to see a step-up in both top line and bottom line, with EBITDA margins expected to recover from a Q3 aberration. - Diagnostics segment growth faces competition but other verticals like pharma, food, environment, and electronics testing expected to continue strong growth. - Continued investment in analytical technologies and expansion in electronics testing and pharma services will support earnings growth. - Management expects to retain or improve current EBITDA margins with growing top line. - Capital expenditure plans for FY24 under review; no major equity raise planned immediately for capex. Overall, steady revenue and earnings growth with margin improvement anticipated in coming years.

- No finalized plans for new fundraising through equity or debt as of the date of this call. - The company is currently in the process of planning for capex but has not finalized the next year's capex plans (to be updated around May). - The CFO mentioned about current outstanding loans (~INR 25 crores, mostly secured). - There was no explicit mention of any immediate rights issue or equity raising planned. - The company retains flexibility to scale its investments capex-wise depending on demand, particularly in electronics and EV components testing. - The management prefers to maintain historical cost accounting for fixed assets without immediate revaluation plans. In summary, Vimta Labs Limited currently is not pursuing any new debt or equity fundraising but is assessing capex and growth needs for the near future.